Ventripoint Diagnostics Ltd is a medical device company that is primarily engaged in the development and commercialization of cardiac diagnostic tools. It sells its products worldwide.
Shares Outstanding 155M
Shares Fully Diluted 178M
Recent Share Price CDN$.53 (US$.42)
52-Week Range CDN$.07-.68
Market Cap ca. CDN$90M (USD$70M)
Symbol: TSX-V: VPT & OTC: VPTDF
Staying true to our story, Ventripoint Diagnostics Ltd. continues to be dedicated to developing quality, smart tools that help solve the immediate needs of our healthcare clinicians, and most importantly improves the clinical experience for our youngest to oldest patient.
Ventripoint has entered into a collaboration with the Veterinary Hospital at the North Carolina State University (NCSU) to test and evaluate the use of the VMS+ in echocardiography of canines with the goal of expanding this technology to all animals.
VMS+ could eventually help treat our most loyal best friend.
EXPLORING NEW FRONTIERS FOR VMS+
Ventripoint Diagnostics Update and Q&A with George Adams, Alvira Macanovic and Dr. Mark Swaim
BioPub/Torrey Hills Capital Zoom Webinar
Topic: Ventripoint: Bigger and Better, with CEO Dr. George Adams